Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Tenax Therapeutics (NASDAQ: TENX), a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, will participate in the Cantor Global Healthcare Conference 2025. The company's presentation will take the format of a fireside chat featuring President & CEO Chris Giordano and Chief Medical Officer Dr. Stuart Rich.
The presentation is scheduled for September 4, 2025, at 10:20 a.m. ET in New York. Investors can access both the live and archived webcast through the company's investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX), azienda farmaceutica in fase clinica di Fase 3 specializzata in terapie cardiopolmonari, parteciperà al Cantor Global Healthcare Conference 2025. La presentazione avrà la forma di una fireside chat con Chris Giordano, Presidente e CEO, e Dr. Stuart Rich, Chief Medical Officer.
L'intervento è programmato per il 4 settembre 2025 alle 10:20 ET a New York. Gli investitori potranno seguire la webcast in diretta e l'archivio tramite la pagina investor relations della società.
Tenax Therapeutics (NASDAQ: TENX), compañía farmacéutica en fase de desarrollo Fase 3 centrada en terapias cardiopulmonares, participará en la Cantor Global Healthcare Conference 2025. La presentación será una charla informal (fireside chat) con Chris Giordano, Presidente y CEO, y Dr. Stuart Rich, Chief Medical Officer.
La presentación está programada para el 4 de septiembre de 2025 a las 10:20 a. m. ET en Nueva York. Los inversores podrán acceder a la retransmisión en directo y al archivo en la página de relaciones con inversores de la compañía.
Tenax Therapeutics (NASDAQ: TENX)는 심폐 치료제에 주력하는 3상 개발 단계 제약사로 Cantor Global Healthcare Conference 2025에 참여합니다. 발표는 사장 겸 CEO 크리스 지오다노(Chris Giordano)와 의학책임자 Dr. Stuart Rich의 파이어사이드 채팅 형식으로 진행됩니다.
발표는 2025년 9월 4일 오전 10시 20분(동부시간), 뉴욕에서 예정되어 있습니다. 투자자들은 회사 투자자 관계 웹페이지를 통해 생중계 및 녹화 영상을 시청할 수 있습니다.
Tenax Therapeutics (NASDAQ: TENX), société pharmaceutique en phase de développement clinique Phase 3 spécialisée dans les thérapies cardiopulmonaires, participera à la Cantor Global Healthcare Conference 2025. La présentation prendra la forme d'un fireside chat avec Chris Giordano, Président et CEO, et Dr. Stuart Rich, Chief Medical Officer.
La présentation est prévue le 4 septembre 2025 à 10h20 (HE) à New York. Les investisseurs pourront accéder à la diffusion en direct et à l'archive via la page relations investisseurs de la société.
Tenax Therapeutics (NASDAQ: TENX), ein Pharmaunternehmen in Phase‑3-Entwicklung mit Schwerpunkt auf kardiopulmonalen Therapien, wird an der Cantor Global Healthcare Conference 2025 teilnehmen. Die Präsentation erfolgt im Format eines Fireside Chats mit Präsident & CEO Chris Giordano und Chief Medical Officer Dr. Stuart Rich.
Der Termin ist für den 4. September 2025 um 10:20 Uhr ET in New York angesetzt. Investoren können das Live‑Webcast sowie das Archiv über die Investor‑Relations‑Seite des Unternehmens aufrufen.
- None.
- None.
CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025, which is taking place from September 3-5, 2025, in New York, NY.
Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer
Date and Time: September 4, 2025, at 10:20 a.m. ET
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
FAQ
When is Tenax Therapeutics (TENX) presenting at the Cantor Global Healthcare Conference 2025?
Who will represent Tenax Therapeutics (TENX) at the Cantor Healthcare Conference?
How can investors access the Tenax Therapeutics (TENX) presentation at the Cantor Conference?
What is Tenax Therapeutics' (TENX) current development stage?
